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Globally prevalent PfMDR1 mutations modulate
Plasmodium falciparum susceptibility to
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Antimalarial chemotherapy, globally reliant on artemisinin-based combination therapies
(ACTs), is threatened by the spread of drug resistance in Plasmodium falciparum parasites.
Here we use zinc-ﬁnger nucleases to genetically modify the multidrug resistance-1
transporter PfMDR1 at amino acids 86 and 184, and demonstrate that the widely prevalent
N86Y mutation augments resistance to the ACT partner drug amodiaquine and the former
ﬁrst-line agent chloroquine. In contrast, N86Y increases parasite susceptibility to the partner
drugs lumefantrine and meﬂoquine, and the active artemisinin metabolite dihydroartemisinin.
The PfMDR1 N86 plus Y184F isoform moderately reduces piperaquine potency in strains
expressing an Asian/African variant of the chloroquine resistance transporter PfCRT.
Mutations in both digestive vacuole-resident transporters are thought to differentially
regulate ACT drug interactions with host haem, a product of parasite-mediated haemoglobin
degradation. Global mapping of these mutations illustrates where the different ACTs could
be selectively deployed to optimize treatment based on regional differences in PfMDR1
haplotypes.
DOI: 10.1038/ncomms11553 OPEN
1 Department of Microbiology and Immunology, Columbia University Medical Center, Room 1502 HHSC, 701 West 168th Street, New York, New York 10032,
USA. 2 Life and Health Sciences Research Institute (ICVS), School of Health Sciences and ICVS/3B’s—PT Government Associate Laboratory, University of
Minho, Gualtar Campus, 4710-057 Braga, Portugal. 3 Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, Box 82,
630 West 168th Street, New York, New York 10032, USA. 4 Research School of Biology, Linnaeus Way, The Australian National University, Acton Australian
Capital Territory 2601, Australia. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to D.A.F.
(email: df2260@cumc.columbia.edu).
NATURE COMMUNICATIONS | 7:11553 | DOI: 10.1038/ncomms11553 |www.nature.com/naturecommunications 1
M
alaria in 2015 was responsible for an estimated 214
million cases and 438,000 deaths1. Fatal cases, resulting
primarily from infection with the Apicomplexan
parasite Plasmodium falciparum, are half those occurring 15
years ago, primarily as a result of the global adoption of highly
effective artemisinin (ART)-based combination therapies (ACTs).
These ACTs combine a fast acting but rapidly cleared ART
derivative with a longer-lasting partner drug. The major partner
drugs are lumefantrine (LMF, which combined with artemether
(ATM) constitutes the most widely used ACT), meﬂoquine
(MFQ, paired with artesunate (AS)), amodiaquine (ADQ, also
paired with AS) and piperaquine (PPQ, combined with the active
ART metabolite dihydroartemisinin (DHA)). These drugs share
certain chemical features such as the 4-aminoquinoline ring
present in ADQ and PPQ (as well as chloroquine, CQ) or the
arylaminoalcohol group present in LMF and MFQ (Fig. 1), and
appear to interact with the parasite haem detoxiﬁcation pathway2.
These interactions might only be a part of complex modes of
action, such as for MFQ (and possibly LMF) where activity
against a cytosolic target (or targets) has been evoked3. In the case
of ART derivatives, these are activated by the central Fe2þ atom
present in haem on its release from haemoglobin4.
In a direct threat to malaria control programmes, ACT
resistance is now emerging, led by P. falciparum resistance to
the ART derivatives. This resistance, which manifests as relatively
slow rates of parasite clearance following treatment, is now
widespread in the Greater Mekong Sub-region5, raising concerns
about its possible spread into the African continent where
malaria exerts its heaviest toll. Epidemiological and molecular
genetic studies have recently shown that ART resistance is
primarily mediated by mutations in the propeller domain of the
P. falciparum K13 kelch protein5–8. Reduced ART efﬁcacy in turn
places increased selective pressure on the ACT partner drugs,
placing them at greater risk of failing. Indeed, PPQ resistance has
now emerged in K13-mutant parasites, resulting in treatment
failure with DHAþPPQ—the ﬁrst-line drug in Cambodia and
several neighbouring countries9–11. Despite an active antimalarial
drug discovery and development pipeline, there is at present
no drug ready to take the place of ACTs should they begin to
fail globally12.
Delineating the role of the P. falciparum multidrug resistance-1
gene pfmdr1 is of particular relevance due to its suspected
involvement in parasite susceptibility to each of the ACT
partner drugs mentioned above, as well as its association with
altered susceptibilities of trophozoite-stage parasites to ART
derivatives13–15. These ﬁndings, acquired in molecular
epidemiology studies, implicate mutant PfMDR1 in multidrug
resistance phenotypes. The interpretation of these earlier studies,
which largely relied on typing single nucleotide polymorphisms
(SNPs), is tempered by the lack of complete PfMDR1 haplotypes.
Studies of isogenic parasites engineered to differ only at their
pfmdr1 locus have the beneﬁt of reducing the genetic complexity
and attributing changes in drug susceptibility to the introduced
sequence changes. Such studies have become more technically
feasible since the advent of genome editing in P. falciparum,
which signiﬁcantly increases the speed and precision with which
SNPs can be exchanged at a gene of interest16.
PfMDR1 is an ATP-binding cassette transporter and a
homologue of the human multidrug-resistance-conferring
P-glycoprotein. It is 1,419 amino acids in length (for the 3D7
isoform) and contains 12 putative transmembrane domains.
PfMDR1 and the pleiotropic drug resistance transporter PfCRT
both reside on the membrane of the parasite’s digestive vacuole
(DV), where they are thought to regulate the ﬂux of solutes across
this membrane17. Their functional relatedness is evidenced by the
linkage disequilibrium seen between certain combinations of
pfmdr1 and pfcrt alleles18,19. This might serve to maximize drug
resistance phenotypes and/or reﬂect compensatory mutations
that reduce any negative impact of mutations in one transporter
on DV physiology or parasite growth. In a genetic cross
between clones of South American (HB3, CQ sensitive) and
Asian (Dd2, CQ resistant) origin, pfcrt was identiﬁed as the
primary determinant of CQ resistance, with the K76T mutation
being ubiquitous to the CQ-resistant progeny20. A separate cross
between CQ-resistant clones from South America (7G8) and
Africa (GB4; having a higher degree of CQ resistance than 7G8)
revealed that the South American pfcrt and pfmdr1 alleles
combine to confer high-level resistance to monodesethyl-ADQ
(md-ADQ), the active ADQ metabolite19.
Studies of pfmdr1 have identiﬁed ﬁve globally prevalent amino
acid mutations. The amino-terminal mutations (N86Y and
Y184F) are more common to Asian and African parasites,
whereas the three carboxy-terminal mutations (S1034C, N1042D
and D1246Y) are found more often in South American isolates
(D1246Y is nonetheless present in B3% of the 1,502 African
genomes recently sequenced by the MalariaGEN consortium; see
below). The ability of PfMDR1 variants to inﬂuence antimalarial
drug potency is supported by heterologous expression systems
that provide evidence of drug transport by certain PfMDR1
isoforms21,22.
Earlier transfection studies have delineated the role of the
C-terminal PfMDR1 mutations in modulating P. falciparum
response to antimalarial drugs including MFQ, ART, CQ and
quinine (QN)23,24. Attempts to modify the N-terminal mutations
were unsuccessful, presumably because the former single-site,
cross-over-based strategies necessitated changes to the pfmdr1
regulatory elements that proved unsuitable for parasite growth24.
That restriction has been negated with the development of zinc-
ﬁnger nucleases (ZFNs), which permit precise gene editing by
triggering a speciﬁc double-stranded break adjacent to the
targeted SNP. Homology-directed recombination can then be
leveraged to repair the DNA lesion, without requiring the
modiﬁcation of any gene regulatory elements or the permanent
integration of a selectable marker25. This approach has been
successfully used to deﬁne the role of the resistance mediators
pfcrt, k13 and pi4k7,26–28. Here we report its successful use to
engineer pfmdr1 N86Y and Y184F mutations in parasite strains
that express the two major CQ resistance-conferring PfCRT
variants. We also use publicly available data from 2,512
P. falciparum genomes to explore the distribution of PfMDR1
haplotypes at positions 86 and 184 in endemic regions.
Our results show that the N86Y mutation contributes to
DHA
Artemether  
Artesunate
R
O
O O O
Chloroquine
Lumefantrine Mefloquine
Amodiaquine Piperaquine
F
FF
N
F
F
F
HO
N
Cl N
N
N N
N
N Cl
HN
NCl
OH
N
Cl N
HN
N
Cl
N
OH
Cl
Cl
R = OH
R = OCH3
R = OCOC2H4COOH
Figure 1 | Chemical structures of antimalarials used in ACTs. Clinically
used artemisinin derivatives are shown on the top left. DHA,
dihydroartemisinin.
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resistance to CQ and ADQ, while sensitizing parasites to LMF,
MFQ and DHA. In contrast, the Y184F mutation has a limited
impact. When combined with the genome analyses, these ﬁndings
help inform the selection of optimal treatment regimens based on
an assessment of local drug selective pressures and the geographic
distribution of PfMDR1 haplotypes.
Results
Geographical distribution of PfMDR1 haplotypes. Recent
advances in whole-genome sequencing and genome analysis,
applied to thousands of P. falciparum genomes by the
MalariaGEN consortium8,29, permit a detailed investigation of
PfMDR1 haplotypes across malaria-endemic regions of Southeast
Asia and Africa (large-scale genome data from South American
and Western Paciﬁc strains are not yet available). By analysing
2,512 parasite genomes made available by this consortium
(www.malariagen.net/pf3k), we determined the frequencies of
the four PfMDR1 haplotypes differing at residues 86 and 184
across multiple countries (Fig. 2 and Supplementary Table 1).
We used the N86/Y184 (NY) haplotype of the drug-sensitive
reference strain 3D7 as the wild-type comparator. Results show
three of the four haplotypes at positions 86 and 184 being
relatively common across West Africa, with only N86Y/Y184
PfMDR1 (YY) being relatively rare. All four were observed in the
Congo in Central Africa, while Malawi in East Africa essentially
lacked the N86Y mutation and harboured only N86/Y184F (NF)
and NY. In Southeast Asia the N86Y mutation was also strikingly
absent (although it remained to the west in Bangladesh) and the
Y184F mutation varied in prevalence from 450% in Cambodia
to o4% in Laos. Southeast Asian isolates quite often also
harboured multiple copies of pfmdr1 (155/1,010 genomes), more
so in parasites with the NY haplotype and never with the N86Y
mutation (Fig. 2 and Supplementary Table 1). This was most
apparent in Thailand, where nearly 40% of all genomes had
ampliﬁed pfmdr1, with as many as ﬁve tandem copies. Ampliﬁed
pfmdr1 was exceedingly rare in Africa (observed in 12/1,502
genomes), potentially because of a ﬁtness cost that is not
conducive to its maintenance in African high-endemicity
settings30. Parallel assessment of pfcrt codon 76 revealed that
98% of all sampled parasites in Southeast Asia carried the K76T
mutation (Table 1 and Supplementary Table 1). Surveys of
African parasites revealed far greater heterogeneity. Parasites
from Malawi were exclusively K76, consistent with strict
removal of CQ pressure31, whereas other countries such as
the Congo maintained the K76T CQ resistance marker in 71% of
the sampled isolates.
Targeted modiﬁcation of pfmdr1. Using customized ZFNs, we
generated two sets of pfmdr1-edited parasites at codons 86 and
184 (Table 2). These sets represented the two major geographic
variants of mutant PfCRT, namely SVMNT and CVIET
(spanning codons 72–76). ZFNs were engineered to bind
neighbouring sites on opposite strands of pfmdr1, producing a
double-stranded break 42 bp downstream of the start codon.
As previously documented, double-stranded break repairs
proceed via homology-directed recombination in P. falciparum,
which lacks the alternative non-homologous end-joining repair
pathway25. Our homology-driven repair template consisted of a
2.4-kb pfmdr1 fragment that encompassed codons 86 and 184.
To prevent ZFNs from cleaving the plasmid or the edited locus,
three silent (non-synonymous) mutations were engineered into
the donor sequence at the ZFN-binding site.
P. falciparum-infected red blood cells (RBCs), predominantly
ring stages, were electroporated with the pmdr1 ZFN plasmids
that also express human dihydrofolate reductase (hDHFR).
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Figure 2 | Geographical distribution of PfMDR1 haplotypes at residues 86 and 184 and pfmdr1 copy number variations. Data were compiled using the
Sanger Pf3k data set (www.malariagen.net/apps/pf3k/release_3/index.html)8,29 and comprised 2,512 genomes. Pie charts represent proportions of
PfMDR1 haplotypes (numerical data per country in Supplementary Table 1). Country colourings show average pfmdr1 ampliﬁcation compared with the 3D7
reference genome with single-copy pfmdr1. Vertical bars in Southeast Asia show the proportions of haplotypes represented among pfmdr1 copy number
variants. Vertical bars colouring: White: no pfmdr1 ampliﬁcation; blue: pfmdr1 ampliﬁcation plus NY haplotype; red: pfmdr1 ampliﬁcation plus NF haplotype.
Countries where PfMDR1 individual polymorphism data are available via WWARN (www.wwarn.org/tracking-resistance/molecular-surveyor-pfmdr1-pfcrt)
are indicated in grey (data not evaluated herein due to the lack of combined N86 and Y184 status in the full data set).
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This selectable marker mediates resistance to WR99210, which
was applied for 4–6 days, to select for transformed parasites. PCR
screening was used to identify edited parasites, which were cloned
by limiting dilution. Figure 3 illustrates the ZFN strategy and
shows representative electropherograms of pfmdr1 editing events.
Editing of pfmdr1 was performed with the P. falciparum NF10
and KC5 clones. These are progeny of the genetic cross between
7G8 (Brazil) and GB4 (Ghana) parasites (Table 2)32. Both progeny
lines inherited a single copy of the GB4 pfmdr1 allele, which
encodes the N86Y/Y184F haplotype (YF). NF10 inherited the
CVIET PfCRT haplotype that is predominant in Asia and Africa,
whereas KC5 harbours the SVMNT haplotype that is highly
prevalent in South America and the Western Paciﬁc. These
progeny differ in their level of CQ resistance and their response to
QN and ADQ19 (see below). Parasites were transfected with four
different pmdr1 plasmids to generate the four different haplotype
combinations, namely YF, YY, NF and NY, in both pfcrt genetic
backgrounds. The resulting lines are denoted NF10mdr1-YF
(recombinant control), NF10mdr1-YY, NF10mdr1-NF, NF10mdr1-NY,
KC5mdr1-YF (recombinant control), KC5mdr1-YY, KC5mdr1-NF and
KC5mdr1-NY (Table 2). Quantitative PCR analysis revealed that all
parasites continued to express a single copy of pfmdr1, with no
change introduced during gene editing (Supplementary Table 2).
In vitro drug susceptibility assays were performed on the
different pfmdr1 recombinant lines. Assays were performed with
two independent clones for each line, with the exception of the
recombinant control lines (NF10mdr1-YF-1 and KC5mdr1-YF-1) and
the KC5mdr1-YY line for which only single clones were recovered.
Drug susceptibility assays used a range of ten compound
concentrations diluted twofold and were performed on ﬁve to
ten separate occasions in duplicate. Numbers of surviving
parasites were quantiﬁed using ﬂow cytometry. IC50 and IC90
values were determined for LMF, MFQ, DHA, PPQ, CQ,
monodesethyl-CQ (md-CQ; the major in vivo metabolite of
CQ), md-ADQ and QN.
Drug assays with gene-edited control parasites carrying only
silent ZFN binding-site mutations showed no change in IC50
values relative to the parental lines (see NF10mdr1-YF-1
versus NF10 and KC5mdr1-YF-1 versus KC5; Figs 4 and 5).
Mean±s.e.m. IC50 and IC90 values, numbers of independent
assays performed and Mann–Whitney tests for statistical
signiﬁcance are listed in Supplementary Tables 3–6. Control
assays with the antimalarial drug atovaquone, which targets the
mitochondrial bc1 complex33, showed no changes in IC50 values
between any of the pfmdr1 recombinant lines and their parental
controls (Supplementary Fig. 1).
PfMDR1 N86Y increases susceptibility to arylaminoalcohols
and DHA. The most striking phenotype observed with the
replacement of N86Y with the wild-type N86 residue was a sig-
niﬁcant increase in the IC50 and IC90 values for LMF, MFQ and
DHA (Fig. 4 and Supplementary Tables 3–6). The change to N86
resulted in a three- to fourfold increase in the IC50 values for LMF
Table 1 | Prevalence of correlated PfCRT-PfMDR1 haplotypes.
PfCRT haplotype PfMDR1 haplotype African correlation Southeast Asian correlation
72 73 74 75 76 86 184 Prevalence (isolates) Prevalence (isolates)
C V M N K Y F 8.4% (126) ND
C V M N K Y Y 1.8% (27) ND
C V M N K N F 39.4% (592) 0.2% (2)
C V M N K N Y 20.9% (314) 1.7% (16)
C V I E T Y F 8.1% (121) ND
C V I E T Y Y 3.1% (46) 0.1% (1)
C V I E T N F 9.4% (141) 40.7% (391)
C V I E T N Y 6.8% (102) 39.7% (381)
C V I D T Y F ND ND
C V I D T Y Y ND ND
C V I D T N F ND 2.1% (20)
C V I D T N Y ND 15.1% (145)
Total 97.9% (1,469) 99.6% (956)
ND, not detected.
This table illustrates the major PfCRT and PfMDR1 haplotypes in Asian and African isolates whose genome sequences have been deposited in the Pf3k database (www.malariagen.net/pf3k). The
remaining minor fractions consist of non-canonical PfCRT haplotpyes.
Table 2 | Haplotypes of PfMDR1-modiﬁed and control clones.
Parasite Plasmid Altered PfMDR1 PfMDR1 haplotype PfCRT haplotype
86 84 1034 1042 1246 72 73 74 75 76
NF10 (YF) None No Y F S N D C V I E T
NF10mdr1-YF pmdr1YF No Y F S N D C V I E T
NF10mdr1-YY pmdr1YY Yes Y Y S N D C V I E T
NF10mdr1-NF pmdr1NF Yes N F S N D C V I E T
NF10mdr1-NY pmdr1NY Yes N Y S N D C V I E T
KC5 (YF) None No Y F S N D S V M N T
KC5mdr1-YF pmdr1YF No Y F S N D S V M N T
KC5mdr1-YY pmdr1YY Yes Y Y S N D S V M N T
KC5mdr1-NF pmdr1NF Yes N F S N D S V M N T
KC5mdr1-NY pmdr1NY Yes N Y S N D S V M N T
GB4 None (Parent) No Y F S N D C V I E T
7G8 None (Parent) No N F C D Y S V M N T
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and MFQ in both the NF10 and KC5 backgrounds (Po0.001,
Mann–Whitney U-test).
In the case of DHA, the change to N86 resulted in B1.5-fold
increased IC50 values in both backgrounds (Po0.05). NF10
recombinant and parental lines were also subjected to in vitro
survival assays, whereby highly synchronized early ring stages
(0–3 h post-invasion) or trophozoites (18–21 h post-invasion)
were exposed to 700 nM DHA for 6 h, followed by washing to
remove drug and assessment of parasite growth 66 h later34.
Results from three independent RSA0–3h and TSA18–21h assays
found no signiﬁcant difference between the various PfMDR1
haplotypes (Supplementary Fig. 2). As a control, we included the
Cam3.IIR539T line, which expresses the K13 R539T mutation that
confers in vitro ring-stage resistance to DHA7. These results
provide evidence that the differences observed in the 72 h in vitro
inhibition assays did not translate into survival beneﬁts on
short-term exposure to a concentration of DHA.
PfMDR1 N86Y decreases susceptibility to CQ and md-ADQ.
Our assays revealed that the parental NF10 line was less sensitive
to CQ, md-CQ and QN but was more sensitive to md-ADQ when
compared with the parental KC5 line. This is consistent with
earlier studies of the 7G8GB4 cross19 that attributed these
changes to the combined effects of PfCRT and PfMDR1. In the
case of the NF10 and KC5 progeny that harbour the same
PfMDR1 YF haplotype, these differences in drug response can be
attributed primarily to mutations in PfCRT (CVIET and
SVMNT, respectively). The replacement of N86Y with the wild-
type N86 residue resulted in increased susceptibility to CQ, md-
CQ and md-ADQ with the greatest difference being observed in
the NF10 recombinant parasites (Fig. 4).
For QN and PPQ, increased susceptibility was also observed on
replacement of the N86Y to N86 in the NF10 line. However, this
difference reached signiﬁcance in only one of the NF and NY
recombinant clones (NF-2 and NY-2) for QN (Po0.05,
Mann–Whitney U-test; Fig. 5) and only in the NY recombinant
line for PPQ (Po0.01; Fig. 4). We also investigated whether the
PfMDR1 N86Y and Y184F mutations affected the accumulation
of radiolabelled CQ, QN or ADQ in recombinant NF10 parasites.
These assays revealed no statistically signiﬁcant effect of the
N-terminal PfMDR1 mutations on the accumulation of these
drugs by trophozoite-infected RBCs (Supplementary Fig. 3).
PfMDR1 Y184F has a minor impact on drug response.
Compared with the N86Y mutation, the Y184F mutation in
PfMDR1 appears to have a weaker association with antimalarial
effectiveness in vivo13,35. Consistent with these observations, we
report that differences in the antimalarial IC50 values between
parasite lines expressing the PfMDR1 184 wild-type or mutant
residue were dependent on the status of residue 86, the class of
drug and the pfcrt genetic background (Figs 4 and 5, and
Supplementary Tables 3 and 4). In lines expressing N86Y,
the presence of Y or F at position 184 had no detectable
inﬂuence on parasite susceptibility to the drugs tested (P40.1,
Mann–Whitney U-test). In parasites with N86, isogenic Y184F
and Y184 lines were generally very similar in their IC50 values for
most drugs, with some exceptions presented below.
In the KC5 background, clones expressing the PfMDR1
NF haplotype presented slightly reduced IC50 values for LMF
and MFQ when compared with the NY clones (Fig. 4 and
Supplementary Table 4). In the NF10 background, the PfMDR1
NF clones exhibited higher IC50 values relative to the NY clones
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for CQ and PPQ, with signiﬁcance achieved in one of the
recombinant clones tested (Supplementary Table 3). As discussed
below, this possible decrease in PPQ susceptibility in parasites
expressing the PfMDR1 NF haplotype in the CVIET PfCRT
background is consistent with the high prevalence of NF parasites
in Cambodia, where PPQ is widely used.
In absolute numbers, our data revealed changes in
susceptibility that remained within commonly employed cutoffs
of resistance for CQ36 (IC50 values above 80 nM) or sensitivity for
MFQ37 (IC50 values below 15 nM). Nevertheless, drug responses
in our genome-edited parasites presented a notable fold change
(up to fourfold for some of the drugs tested). Although these
relative changes might not sufﬁce to cause clinical failure, they
may contribute to clinical outcome, in conjunction with other
infection variables.
PfMDR1 F1226Y shows no impact on in vitro drug response.
Recent studies have identiﬁed nearly 50% prevalence of the
PfMDR1 F1226Y mutation in Thailand and Cambodia, and
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Figure 4 | In vitro IC50 response of pfmdr1-modiﬁed and parental lines. IC50 values (nM) were determined by incubating parasites for 72 h across a range
of drug concentrations. Parasite growth was determined by measuring parasitaemia using ﬂow cytometry with cells stained with Mito Tracker Deep Red
and SYBR Green. Mean±s.e.m. IC50 values are presented for lumefantrine (LMF), meﬂoquine (MFQ), dihydroartemisinin (DHA) and piperaquine (PPQ).
Five to ten assays were performed for each drug (Supplementary Tables 3 and 4). Statistical evaluations comparing mutant pfmdr1-modiﬁed lines against
recombinant control lines of the same genetic backgrounds (NF10mdr1-YF-1 and KC5mdr1-YF-1 for NF10 and KC5 lines, respectively) were performed using
two-tailed Mann–Whitney U-tests. *Po0.05, **Po0.01 and ***Po0.001.
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suggested its contribution to altered antimalarial drug
susceptibilities38,39. To examine the role of this mutation in vitro,
we employed a single cross-over-based allelic exchange strategy to
introduce the PfMDR1 F1226Y mutation into the CQ-resistant
K1 strain (obtained from Thailand in the early 1980s), which
harbours a single copy of pfmdr1 with YYSNFD at positions 86,
184, 1034, 1042, 1226 and 1246 (Supplementary Fig. 4).
Phenotypic assessment of the parental strain and the F1226Y
recombinant lines revealed no difference in the IC50 values for
any of the drugs tested (LMF, MFQ, ART, AS, PPQ, CQ,
md-ADQ and QN; Supplementary Table 7). Further studies will
be required to assess whether this mutation might have an impact
on drug susceptibilities in other Asian parasites, especially given
that these no longer harbour the N86Y mutation and are often
pfmdr1 multicopy (Fig. 2).
Discussion
Our study of genetically engineered P. falciparum lines with
isogenic controls provides direct evidence that the PfMDR1
mutation N86Y modulates parasite susceptibility to a wide
range of ﬁrst-line antimalarials. We demonstrate that the N86Y
mutation increases parasite susceptibility to LMF, MFQ and
DHA, and conversely augments resistance to md-ADQ and CQ.
The PfMDR1 Y184F mutation had a notably lesser impact in
our isogenic lines, with evidence of decreasing P. falciparum
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susceptibility to PPQ when paired with the N86 residue.
These data, which resolve long-standing questions about the role
of PfMDR1, provide a foundation for improved molecular
surveillance of antimalarial drug resistance and help inform
region-speciﬁc decisions on which ACTs to employ.
The most striking effect of N86Y was on susceptibility to LMF
and MFQ, for which parasites engineered to express wild-type
N86 showed three- to fourfold higher drug IC50 values compared
with the mutant N86Y residue. These data conﬁrm genotyping
and drug association studies performed with African and Asian
isolates40,41, and are consistent with reports that the N86 allele
predominates in recurrent infections following treatment with
ATMþ LMF13,42. Indeed, a recent meta-analysis of 31 clinical
trials revealed that patients infected with N86 parasites had a
ﬁvefold greater risk of parasite recrudescence following
ATMþ LMF treatment compared with those infected with
N86Y parasites15. Those data illustrate the utility of the in vitro
data generated herein in identifying susceptibility shifts that
correlate with changes in clinical outcomes.
The N86Y mutation was also observed to alter the parasite
response to DHA, with B1.5-fold decreased IC50 values
compared with isogenic N86 parasites. Previous in vitro studies
on laboratory strains and clinical isolates have also noted cross-
resistance between MFQ, LMF and ART derivatives23,24,35. This
differs from the ART resistance mediated by mutations in K13,
which manifests as reduced ring-stage susceptibility to DHA6,7.
The IC50 shifts observed here are likely to reﬂect a role for pfmdr1
in reducing parasite susceptibility at the trophozoite stage when
haemoglobin degradation is the most active, producing high
intracellular concentrations of the ART-activating ferrous iron
that resides within haem43.
In contrast to our ﬁnding that the N86Y mutation increases
parasite susceptibility to LMF, MFQ and DHA, we observed that
this mutation decreases parasite susceptibility to CQ, md-CQ and
md-ADQ in the NF10 background. CQ resistance has earlier
been proposed to have some degree of association with the
N86Y mutation, both in South American and Asian/African
backgrounds44. Previous studies with patient isolates have also
linked the N86Y mutation to reduced parasite susceptibility to
ADQ45,46. Our data reveal that the effect of the N86Y mutation
on parasite response to CQ and md-CQ is signiﬁcant in parasites
expressing the CVIET PfCRT variant. This effect, however, is
modest in parasites expressing the SVMNT PfCRT variant.
The latter observation is probably due, at least in part, to
differences in the kinetics of PfCRT-mediated CQ and md-CQ
transport between the high-capacity CVIET transporters and the
low-capacity SVMNT transporters47. This possibility is discussed
in more detail below and in Fig. 6.
The involvement of residue 86 in QN resistance has been
controversial48,49. Our results indicate that residue 86 of PfMDR1
plays a minor, background-speciﬁc role in QN susceptibility, with
N86Y producing a slight increase in QN resistance only in NF10
parasites (that carry CVIET PfCRT). Mutant PfCRT is known to
contribute to QN resistance, although the full repertoire of
parasite determinants remains to be identiﬁed48,50,51.
Whereas the N86Y mutation affected the susceptibility of
parasites to CQ and md-ADQ (and to a lesser extent QN), N86
and N86Y clones in the NF10 background showed no discernible
difference in their accumulation of radiolabelled CQ, ADQ or QN
(Supplementary Fig. 3). This suggests that if PfMDR1-mediated
drug transport was occurring in parasites expressing a given
PfMDR1 variant, the impact on drug accumulation was modest
and beyond the limits of assay detection. Our data recall a prior
analysis of the progeny of the GB4 7G8 genetic cross, which
found that pfmdr1 alleles could affect parasite drug susceptibility
(as quantiﬁed using IC50 assays) without signiﬁcantly altering
levels of drug accumulation51. These ﬁndings suggest that
polymorphisms within PfMDR1 and PfCRT can contribute to
resistance phenotypes through mechanisms based not only on
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Figure 6 | Proposed roles for PfMDR1 and PfCRT in the P. falciparum
response to CQ and LMF. (a) CQ (a weak base) and the hydrophobic drug
LMF are thought to enter the DV via simple diffusion across the membrane.
Within the DV, CQ is thought to trigger parasite killing by binding to reactive
haem moieties and preventing their biomineralization into chemically inert
haemozoin crystals67. LMF also shows moderate binding to haem2; however,
its main site of action is suspected to be outside of the DV. It is thought that
PfCRT facilitates the efﬂux of drugs from the DV, and that PfMDR1 transports
drugs into the DV3,68. (b–e) Point mutations in these transporters are known
to differentially impact parasite susceptibility to CQ and LMF. The N86Y
mutation is thought to ablate PfMDR1-mediated CQ transport activity22, but
the resulting reduction in the rate of CQ inﬂux is insufﬁcient to confer CQ
resistance in parasites that carry wild-type PfCRT (designated as K76)47
(b,c). CQ resistance-conferring isoforms of PfCRT (designated K76T) mediate
the efﬂux of CQ from the DV68–70. The reduced rate of CQ inﬂux in PfMDR1
N86Y parasites may further decrease CQ concentrations in the DV and thus
augment CQ resistance. However, this effect is only evident in parasites
expressing a high-capacity transporter of CQ (for example, GB4 PfCRT)47.
This is perhaps because the loss of CQ inﬂux via PfMDR1 causes a substantial
decrease in the time taken to reach sub-lethal levels of CQ in the DV only
when the drug is being extruded from the DV via K76T PfCRT at a relatively
high rate. (e) LMF might also be a substrate of PfMDR1 N86 (b,d) and the
introduction of N86Y (c,e) might likewise reduce the capacity of PfMDR1 to
import LMF into the DV. In this scenario, the heightened susceptibility of CQ-
resistant N86Y PfMDR1 parasites to LMF could be due to the increased
accumulation of LMF in the cytosol (where its main antimalarial target may be
located). The relative sizes of the CQ and LMF text in these panels reﬂect the
predicted distribution of the drugs between the DV and cytosol.
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regulating drug accumulation inside the DV. One hypothesis,
for which supporting evidence exists52–54, is that these
antimalarials might bind these transporters directly and inhibit
their physiological function. This mode of action would be in
addition to these drugs interfering with reactive haem
detoxiﬁcation through interactions with haem2.
Our studies also revealed only a minimal impact of the Y184F
mutation on antimalarial drug susceptibilities. In the NF10
background harbouring the predominant Asian/African pfcrt allele,
there was a decreased susceptibility to PPQ in Y184F parasites,
which was observed in the presence of the N86 residue. Structural
models for PfMDR1 place residue 184 in the third transmembrane
domain and it has been hypothesized that the Y184F mutation
might affect the kinetics of PfMDR1-mediated drug transport22,55.
Transport studies in Xenopus oocytes have also provided evidence
of an effect of both the Y184F and N86Y mutations on the ability
of PfMDR1 to transport different drugs22,55. Studies with
proteoliposomes also provide evidence that PfMDR1 or PfCRT
isoforms can differentially bind quinoline drugs52.
Previous studies have used traditional transfection-based
approaches to explore the effects of the C-terminal mutations
S1034C, N1042D and D1246Y on parasite drug responses23,24.
These C-terminal PfMDR1 mutations, which are more frequent
in low-transmission areas in South America than in Asia or
Africa (as obtained from www.malariagen.net/pf3k), were found
to inﬂuence parasite susceptibility to MFQ, QN and ART. These
mutations also had an impact on the parasite’s response to CQ in
some genetic backgrounds23,24. Studies with isogenic transfectant
lines have also revealed that an increase in pfmdr1 copy number,
which is very rare in Africa but which occurs relatively frequently
in parts of Southeast Asia, reduces parasite susceptibility to MFQ,
LMF, QN and ART56. Our study now elucidates the roles of the
other two major PfMDR1 polymorphisms, N86Y and Y184F,
which are the most prevalent variations in Africa. Of note, recent
studies from Uganda have observed selection for PfMDR1 wild-
type N86 and D1246 in patients treated with ATMþ LMF,
contrasting with selection of the mutations N86Y and D1246Y in
patients receiving ASþADQ57. Our evidence that N86Y
increases parasite susceptibility to MFQ and LMF also helps
explain why this mutation is very rarely observed in Thai
parasites that have been under selection with these drugs, and
that often carry multicopy pfmdr1, which has the opposite effect
of reducing susceptibility (Fig. 4 and Supplementary Table 1).
Our efﬁcient gene-editing method now enables the examination
of additional PfMDR1 polymorphisms that have recently been
identiﬁed in ﬁeld isolates, presumably as a result of the change in
the past decade from CQ to ACTs.
Our study lends further support to the notion that the parasite
genetic background is an important factor in determining the
impact of PfMDR1 polymorphisms on parasite drug response.
Studies with progeny of the GB4 7G8 cross have implicated
PfCRT as a major driver of these divergent responses19. Evidence
from heterologous expression studies in Xenopus oocytes suggest
that GB4 PfCRT is a relatively high-capacity transporter of
CQ, whereas the 7G8 isoform has a much lower capacity
(but somewhat higher afﬁnity) for CQ transport47. GB4 PfCRT
might therefore be effective in decreasing high concentrations of
CQ within the DV to sub-lethal levels. In this scenario the
simultaneous action of an additional mechanism for reducing CQ
accumulation—for example, mutations in PfMDR1 that ablate its
ability to import CQ into the DV—could translate into further
increases in the parasite’s resistance to CQ that are attributable to
the PfMDR1 variant. By contrast, 7G8 PfCRT might act more
slowly to reduce CQ concentrations to sub-lethal levels. During
that time the reduced CQ transport activity of the PfMDR1
variant might be mostly or completely masked, because, even
with the reduced rate of CQ inﬂux into the DV, the vacuolar
concentration of CQ would be such that parasite growth and/or
viability is still signiﬁcantly reduced. This is but one possible
mechanistic explanation for our ﬁndings (Fig. 6) and further
studies are required to delineate the mechanisms by which
different variants of PfCRT and PfMDR1 combine to affect drug
susceptibility.
The recent availability of thousands of P. falciparum
genomes now makes it possible to also examine regional
associations between PfMDR1 and PfCRT haplotypes (Table 1
and Supplementary Table 1). In Africa, nearly 70% of the recently
sequenced isolates carried the CQ-sensitive PfCRT CVMNK
(residue 72–76) haplotype, with the remainder carrying the
CQ-resistant CVIET haplotype. This recent resurgence of
CQ-sensitive isolates in Africa that harbour wild-type pfcrt
emphasizes the value of expanding pfmdr1 gene-editing studies
to those parasites. In Africa, the most abundant PfMDR1
N-terminal haplotypes were NF and NY. In Asia, the PfCRT
haplotypes were almost all CVIET (80%) with the remainder being
the CVIDT variant that was observed to have a minimal ﬁtness
cost compared with CVIET parasites58. Asian parasites were
almost all NF or NY, with the latter associating the most with the
CVIDT haplotype.
Our ﬁndings also provide new insights into the ways in which
drug pressures have shaped different parasite populations.
In Thailand, the reliance on ASþMFQ59 might explain why
fewer than 1% of Thai isolates harbour the PfMDR1 N86Y
mutation (Supplementary Table 1), which based on our data
increases parasite susceptibility to both MFQ and DHA, and
which therefore would be selected against. Indeed, MFQ has been
used widely throughout Southeast Asia, which could explain the
overall rarity of the N86Y mutation in this region. Bangladesh is
an exception in that it has a signiﬁcant proportion (22%) of N86Y
isolates. This prevalence may reﬂect the fact that the national
malaria control programme in Bangladesh administers CQ and
QN in addition to ATMþ LMF60. We ﬁnd that PfMDR1 N86Y
decreases parasite susceptibility to both CQ and QN, suggesting
its active selection in this country. The N86Y mutation also
decreases parasite susceptibility to md-ADQ, which could explain
why this mutation is commonly observed in West Africa where
ASþADQ is frequently used. Malawi, on the other hand, relies
on ATMþ LMF as its ﬁrst-line ACT, and in this east African
countryo2% of parasite isolates have the LMF-sensitizing N86Y
mutation. Given the rapid changes in antimalarial drug use in
Africa over the past 15 years, it will be of interest to assess
changes over time in pfmdr1 positions 86, 184 and 1246. The
currently available genome data sets, however, do not currently
permit this chronological analysis. Regarding PfMDR1 184, Laos
is the only Southeast Asian country shown in Fig. 2 that employs
ATMþ LMF as its sole ACT, with the other countries having a
treatment policy that includes the use of DHAþ PPQ61. In light
of our ﬁnding that the NF haplotype is associated with slightly
decreased susceptibility to PPQ in parasites harbouring the
Southeast Asian/African CVIET variant of PfCRT, we propose
that the difference in treatment policies explains the rarity of the
Y184F mutation in Laos (o4% of isolates) and its elevated
frequency (420% of isolates) in the other Southeast Asian
countries that more commonly use DHAþPPQ. Based on our
combined phenotypic and mapping data, we propose that an
optimal policy for ACT usage would entail the use of LMF in
areas with a high proportion of N86Y, ADQ in areas where N86
is prevalent and PPQ in areas with a high frequency of NY
haplotype. The competing selective forces of LMF and ADQ, both
on PfMDR1 and PfCRT15,62, also support scenarios of dual
implementation of ATMþ LMF and ASþADQ, to suppress the
emergence of high-grade multidrug resistance.
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Methods
Analysis of the Pf3k P. falciparum genome data set. Genome analysis used data
generated by the Pf3k project (www.malariagen.net/pf3k)8,29. Assembly ﬁles were
downloaded from ftp://ngs.sanger.ac.uk/production/pf3k/release_3/, a publically
accessible database. SNPs were manually extracted using the annotated Pf3D7
genome version 9.2 (the same used to assemble the ﬁeld isolate genomes) and a
custom Perl script used to call each base, its sample depth and allelic balance.
Indels were not considered. The output was inserted as a table into a MySQL
database that contained Pf3k metadata (including isolate origins and general
mapping quality values). Using bash shell-MySQL connectors, we retrieved
PfMDR1 (PF3D7_0523000) haplotype data from the database in an ordered list
(separated by geographic region) on a per-genome basis. Haplotypes for amino
acids 86 and 184 were counted and visualized in Excel. Copy number variations
(CNVs) were assessed using the programme BICSeq63, incorporated in a shell
script to permit parallel processing. Analysis was performed iteratively against
several reference genomes to ﬁnd the closest match for each ﬁeld isolate. These
included the West African laboratory strain 3D7, the Cambodian isolate PH0164-C
and the Senegalese isolate SenT087.09. PH0164-C has a Southeast Asian PfCRT
haplotype (eight mutations), no pfmdr1 or k13 mutations and no known pfmdr1
CNVs. SenT087.09 has no CNVs, is wild-type for pfcrt and pfmdr1, and carries a
triple mutant pfdhfr (encoding N51I, C59L and S108N) that is common in Africa
and confers pyrimethamine resistance. Default parameters were set to a bin size of
300 nucleotides, a window size of 600 nucleotides and a smoothing factor of 12. To
plot the distribution of CNVs, values were combined per country and separated by
non-CNV-harbouring isolates and CNV-harbouring isolates of a certain haplotype.
The geographical map was downloaded using free spatial data from DIVA-GIS
(http://diva-gis.org) and imported into QGIS 2.10 (http://qgis.org/en/site) to be
merged with the geo-referenced data. This map was overlaid with the previously
calculated haplotypes as pie charts.
Plasmid construction. CompoZr Custom ZFNs were purchased from
Sigma-Aldrich (St. Louis, Missouri, USA) to induce a double-strand break in the
50-end of the pfmdr1 coding sequence. Two ZFNs (left and right), binding to
adjacent sequences on opposite strands of the DNA helix, are required to induce
the double-strand break. These were supplied on separate plasmids. The ZFN pair
was designed to bind to the sequence 50-GGTAACCTCAGTatcaaAGAAGAGG
TTGAAAAAGA-30 (the DNA cut site is shown in lower case letters and is situated
42 bp downstream of the pfmdr1 start codon). The plasmid encoding the right ZFN
also encoded the 2A ‘ribosome skip’ peptide, which enables polycistronic
expression of 2A-linked genes26. The two plasmids encoding the ZFNs were
digested with BglII and XhoI, and combined to yield an intermediate plasmid with
2A-linked ZFN sequences. The ZFN fusion was then digested with NheI and XhoI,
and subcloned downstream of a calmodulin (PF14_0323) promoter and upstream
of the hsp86 (PF07_0030) 30-untranslated region in a pDC2-based vector with the
hdhfr selectable marker26, yielding the plasmid pZFNpfmdr1-hdhfr.
A 2.4-kb donor sequence, encompassing 555 bp of the pfmdr1 50-untranslated
region and 1,805 bp of the pfmdr1 coding sequence, was ampliﬁed from NF54
genomic DNA with the primers p1þ p2 (Supplementary Table 8) and inserted into
the BstAPI and AatII sites of pZFNpfmdr1-hdhfr to yield the editing plasmid pmdr1.
To prevent edited genomes from being further cleaved, three silent mutations were
engineered into the donor sequence at the ZFN-binding site via site-directed
mutagenesis (QuikChange Multi SDM Kit; Agilent Technologies, Santa Clara,
California, USA) using the primers p9þ p10. The donor template, containing the
three silent mutations, was further mutated as required to introduce point
mutations at pfmdr1 codons 86 and 184 (using the primer pairs p11þ p12 or
p13þ p14), yielding four transfection plasmids (Fig. 3).
Parasite culture and transfection. P. falciparum NF10 and KC5 clones (kindly
provided by Dr Thomas E. Wellems, NIH) were maintained at B3% haematocrit
with human Oþ RBCs (Interstate Blood Bank, Memphis, TN, USA) in RPMI-1640
supplemented with 2 g l 1 sodium bicarbonate, 2mM L-glutamine, 25mM HEPES,
10mgml 1 gentamycin, 50mM hypoxanthine and 0.5% (w/v) AlbuMAXII
(Invitrogen, Waltham, Massachusetts, USA). They were maintained at 37 C in an
airtight environment ﬂushed with 5% O2/5% CO2/90% N2. Ring-stage cultures at
5–8% parasitaemia were electroporated with B70 mg of puriﬁed plasmid DNA
eluted in 1 Cytomix, as described26.
Four different plasmids expressing the PfMDR1 86/184 residues (YF, YY, NF or
NY) were used to electroporate NF10 and KC5 cultures. The plasmids were
designed to modify pfmdr1 codons 86 and 184, and to integrate three silent
mutations at the ZFN-binding site. To enable transient ZFN expression and
consequent homology repair, WR99210 (2.5 nM; Jacobus Pharmaceuticals,
Plainsboro, New Jersey, USA) was applied to transfected cultures 24 h
postelectroporation and maintained for 4–6 days. We cloned edited parasites by
limiting dilution in 96-well plates.
DNA analysis. Clones from transfected NF10 and KC5 parasites were checked for
ZFN-mediated editing by PCR ampliﬁcation from genomic DNA using the KAPA
Blood PCR Kit B (KAPA Biosystems, Wilmington, Massachusetts, USA) and the
primers p3 (located upstream of the pfmdr1 start codon and not in the plasmid
‘donor sequence’) and p4 (Supplementary Table 8). The silent mutations
introduced into the donor sequence create an SmlI restriction site, which was used
to screen PCR products. Ampliﬁed fragments containing the silent mutations
were sequenced to conﬁrm editing at codons 86 and 184. Successfully edited clones
were expanded for further analysis. pfmdr1 copy number analysis was performed
using a published Taqman-based quantiﬁcation assay35. 3D7 and FCB were used as
control parasites, as they harbour 1 and 2 copies of pfmdr1, respectively
(Supplementary Table 2).
In vitro antimalarial drug assays. Drug inhibitory assays were performed using a
ﬂow cytometry-based method described previously64, with some modiﬁcations.
Assays were performed in ﬂat-bottom 96-well plates, with each well containing
200 ml of cell suspension in culture medium, with or without the test compound as
appropriate. The starting haematocrit was 1% and the starting parasitaemia
(consisting of predominantly ring-stage parasites) was 0.1–0.2%. After 72 h
incubation at 37 C, samples were analysed by ﬂow cytometry. Cells were stained
with 1.6 mM Mito Tracker Deep Red and 2 SYBR Green (Invitrogen) in
1 PBS64. In vitro IC50 and IC90 values were calculated using nonlinear regression
analysis. In vitro Ring-stage Survival Assay (RSA0–3h) and Trophozoite-stage
Survival Assay (TSA18–21h) were carried out with 700 nM DHA as previously
described7,34. In summary, NF10 recombinant and parental lines were sorbitol and
Percoll synchronized and tested as 0–3 h post-invasion ring stages and 18–21 h
post-invasion trophozoites. Parasites were adjusted to 1% parasitaemia and
exposed to 700 nM DHA for 6 h. After this time, drug was removed by washing and
parasites were cultured a further 66 h. Parasite viability was assessed by ﬂow
cytometry as stated above. RBCs (20,000 to 35,000) were counted in two separate
wells per experiment, which was repeated on three separate occasions7. Percent
survival was calculated as the parasitaemia in the drug-treated sample divided by
the parasitaemia in the untreated sample  100 (Supplementary Fig. 2).
Drug accumulation assays. Assays were performed on mature, intact
trophozoite-infected erythrocytes suspended in bicarbonate-free RPMI 1640
medium (supplemented with 25mM HEPES, 10mM glucose and 0.2mM
hypoxanthine, and adjusted to pH 7.4) at a parasitaemia of 3.7–9.1% and a
haematocrit of 2%. The ﬁnal concentrations of [3H] CQ (20Cimmol 1), [3H]
QN (80Cimmol 1) and [3H] ADQ (15Cimmol 1) were 20, 20 and 40 nM,
respectively. Labelled drugs were purchased from American Radiolabeled
Chemicals. Assays were performed according to a protocol described previously65
with one modiﬁcation: the incorporation of radiolabelled drug into the acid-
insoluble pellets was also measured66 and values included in determinations of the
amount of drug taken up by the cells. Accumulation studies were also attempted
with radiolabelled LMF; however, a high level of variability was observed. This may
have resulted from the poor solubility of LMF in one of the solutions used in the
experiment and/or from the diffusion of LMF into the oil layer that was used to
terminate drug accumulation (the cells are separated from the radiolabelled drug
solution by centrifugation through oil).
Statistical tests. All statistical analyses used non-parametric two-tailed
Mann–Whitney U-tests (normal distribution not assumed; performed with
GraphPad Prism Software).
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